Applicant: Erik Buntinx Serial No.: 10/725,965 Filed: December 2, 2003

page 2 of 19

## Amendments to the Claims:

Please cancel Claims 78, 80, 83 and 85 without prejudice or disclaimer, and amend Claims 41, 42, 79, 81, 82 and 84 as set forth below.

1-40. (Canceled)

- 41. (Currently amended) A pharmaceutical composition <u>for treating a mood</u> <u>disorder or an anxiety disorder</u> comprising:
- (a) pipamperone in a dose of 5-15 mg, a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and
- (b) a selective serotonin re-uptake inhibitor, and a pharmaceutically acceptable carrier.

as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality which is selected from the group consisting of mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders, factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, cognitive disorders, impulse control disorders, pervasive development, attention deficit and disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational, identity, phase of life, academic problem, and problems related to abuse or neglect.

Applicant: Erik Buntinx Serial No.: 10/725,965 Filed: December 2, 2003

page 3 of 19

- 42. (Currently amended) The pharmaceutical composition according to claim 41, wherein the selective serotonin re-uptake inhibitor is citalopram. eomprising:
- (a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient, and
  - (b) citalopram in a dose ranging between 10 and 40 mg of the active ingredient.
  - 43-78. (Canceled)
- 79. (Currently amended) The pharmaceutical composition according to claim <u>42</u>, <del>41,</del> wherein <u>citalopram is in a dose of 10-40 mg</u> the selective serotonin re-uptake inhibitor is citalopram.
  - 80. (Canceled)
- 81. (Currently amended) A pharmaceutical composition <u>for treating a mood</u> <u>disorder or an anxiety disorder comprising: <del>consisting of:</del></u>
- (a) pipamperone in a dose of 5-15 mg, a compound having (i) a selective affinity for the Dopamine 4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5 HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and
- (b) a selective serotonin re-uptake inhibitor, and a pharmaceutically acceptable carrier, wherein pipamperone and the selective serotonin re-uptake inhibitor are the sole pharmaceutically active ingredients in the composition.

Applicant: Erik Buntinx Serial No.: 10/725,965 Filed: December 2, 2003

page 4 of 19

as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality which is selected from the group consisting of mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders, factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, cognitive disorders, impulse control disorders, pervasive development, attention deficit and disruptive behaviour disorders, substance related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational, identity, phase of life, academic problem, and problems related to abuse or neglect.

- 82. (Currently amended) The pharmaceutical composition according to claim 81, wherein the selective serotonin re-uptake inhibitor is citalogram.
- (a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient, and
  - (b) citalopram in a dose ranging between 10 and 40 mg of the active ingredient.
  - 83. (Canceled)
- 84. (Currently amended) The pharmaceutical composition according to claim <u>82</u>, <del>81</del>, wherein <u>citalopram</u> is in a dose of 10-40 mg the selective serotonin re-uptake inhibitor is citalopram.
  - 85. (Canceled)